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ABSTRACT
Background: To examine the angiopoietin pathway inhibitor trebananib IV plus 
the anti-VEGF agents bevacizumab or motesanib in advanced solid tumours.
Methods: In this open-label phase 1b study, patients received IV trebananib 
3 mg kg−1 QW plus bevacizumab 15 mg kg−1 Q3W (cohort 1) or motesanib orally 
75 mg (cohort 2); or trebananib 10 mg kg−1 plus bevacizumab 15 mg kg−1 (cohort 3) or 
motesanib 125 mg (cohort 4). If <33% of patients had dose-limiting toxicities (DLTs), 
dose escalation occurred. Endpoints were treatment–related adverse events (AEs) 
incidence and pharmacokinetics (primary); anti-trebananib antibodies, biomarkers, 
and tumour response (secondary).
Results: Thirty-six patients received ≥1 dose of trebananib (cohorts 1, 2, 3, 4; 
n = 6, 8, 19, 3). DLT of G3 intestinal perforation and G3 tumor haemorrhage occurred 
in cohorts 2 and 3, respectively (both n = 1). Across both trebananib plus bevacizumab 
cohorts, the most common AEs included fatigue (n = 8), diarrhoea (n =4), constipation 
(n = 3), nausea (n = 3), and epistaxis (n = 3). Three patients across those cohorts 
had grade ≥3 AEs. Across the trebananib plus motesanib cohorts, the most common 
AEs included hypertension (n = 4), diarrhoea (n = 4), nausea (n = 3), fatigue 
(n = 3), vomiting (n = 2), and decreased appetite (n = 2). Two patients had grade 
≥3 AEs. Trebananib did not markedly affect motesanib pharmacokinetics. Across the 
trebananib plus bevacizumab cohorts, two patients had a partial response; 11 patients 
had stable disease lasting >6 months. Across the trebananib plus motesanib cohorts, 
one patient had a partial response; five patients had stable disease lasting >6 months.
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Conclusion: Trebananib IV 3 mg kg−1 or 10 mg kg−1 plus bevacizumab or 
motesanib in advanced solid tumours may be associated with less severe toxicities 
relative to those emerging when combining two anti-VEGF agents.
INTRODUCTION
Angiogenesis, the process of formation of new blood 
vessels from the pre-existing vasculature, is critically 
important in tumour development and metastasis [1]. 
Relatively recent approaches in advancing antiangiogenic 
therapies for cancer have involved simultaneous inhibition 
of multiple angiogenic targets in an effort to achieve 
superior efficacy relative to inhibition of single targets. To 
date, these attempts have been limited to the combination 
of anti-VEGF pathway-targeted therapies. While there 
appears to be some suggestion of enhanced efficacy, 
increased toxicities were also observed, likely as a result 
of additive, synergistic, or antagonistic stimulation of the 
VEGF pathway [2]. Moreover, combination treatments 
targeting the same pathway carry the risk of initiating 
compensatory escape mechanisms [3–5]. Preclinical 
research suggests that the combination of an angiopoietin 
inhibitor and an anti–VEGF antibody may enhance 
antitumor activity [6]. It is unknown, however, whether 
such combination therapies would provide an improved 
risk/benefit ratio in the clinical setting.
The angiopoietin pathway is a key regulator of 
angiogenesis [7, 8]. It involves the receptor tyrosine 
kinase, Tie2, which is expressed in a limited number of 
cell types, including the vascular endothelium [9]. Tie2 
binds the ligands Ang1, Ang2, and Ang4, with Ang1 and 
Ang2 being well characterised. While Ang1 appears to 
contribute to vessel maturation and stabilisation [10], 
Ang2 plays a crucial role in vessel destabilisation during 
vascular remodelling [11] and new vessel sprouting [9]. 
Thus, both represent important and complementary 
determinants of angiogenesis. Elevated Ang2 expression 
has been found in tumour vasculature across various 
cancer types and has been associated with disease 
progression [11–13] and worse prognosis [14].
Trebananib, an investigational, intravenously 
administered peptide-Fc fusion protein (“peptibody”), 
inhibits tumour angiogenesis through dual inhibition of 
Ang1 and Ang2, thereby neutralising their interaction with 
the Tie2 receptor. Animal models have demonstrated tumour 
inhibition when trebananib is administered systematically to 
tumour-bearing mice [11]. Importantly, the antitumor effect 
has been shown to be greater with combined inhibition of 
Ang1 and Ang2 compared with blocking of either ligand in 
isolation [15]. Results from a first-in-human dose escalation 
study in patients with advanced solid tumours showed that 
trebananib monotherapy had antitumor activity and was 
tolerated at doses up to 30 mg kg−1 once weekly (QW) with 
a toxicity profile that was distinct from other angiogenesis 
inhibitors, including VEGF pathway inhibitors [16]. The 
most common treatment-related toxicities during trebananib 
monotherapy included peripheral oedema and fatigue; no 
bleeding or thromboembolic events occurred. A randomised 
phase 2 study in patients with recurrent ovarian cancer 
suggested that treatment with trebananib at 3 mg kg−1 or 
10 mg kg−1 QW plus paclitaxel QW may result in improved 
progression-free survival (PFS) relative to placebo plus 
paclitaxel QW, particularly at the higher dose [17]. Again, 
the toxicity profile was distinct and generally manageable.
The current study’s objectives were to assess the 
tolerability, pharmacokinetic (PK) and biomarker profiles, 
and tumour response to trebananib in combination 
with two VEGF pathway inhibitors, the humanised 
recombinant monoclonal antibody bevacizumab 
or small molecule antagonist motesanib, in adult 
patients with advanced solid tumours. Bevacizumab 
inhibits VEGF with demonstrated antitumor activity 
in combination with multiple chemotherapies in 
several cancers such as colorectal and non–small cell 
lung cancer [18, 19]. Motesanib blocks the VEGF 
receptors (VEGFRs)-1, -2, and -3, platelet-derived 
growth factor receptor (PDGFR), and c-Kit [20]. 
In previous studies, motesanib treatment reduced 
tumour burden when administered as monotherapy or in 
combination with chemotherapy [21–23].
RESULTS
Patients
A total of 38 patients were enrolled between 
December 2005 and February 2007: cohort 1 (trebananib 
3 mg kg−1 plus bevacizumab 15 mg kg−1), n = 6); cohort 
2 (trebananib 3 mg kg−1 plus motesanib 75 mg), n = 9; 
cohort 3 (trebananib 10 mg kg−1 plus bevacizumab 
15 mg kg−1) n = 20; and cohort 4 (trebananib 3 mg kg−1 
plus motesanib 125 mg) n = 3. One patient each in cohorts 
2 and 3 did not receive trebananib treatment and, therefore, 
was excluded from all subsequent analyses. Patients 
discontinued the study for the following reasons: disease 
progression (cohorts 1, 2, 3, 4; n = 2, 3, 13, 2), death 
(n = 1, 3, 2, 0), withdrawal of consent (n = 0, 1, 1, 0), 
adverse events (n =  1, 0, 0, 0), and other (n = 2, 2, 4, 1).
Across cohorts 1 through 4, patients received 
a median of 18.5, 9.5, 15.0, and 11.0 weekly doses 
of trebananib, respectively. Cohorts 1 and 3 were 
administered a median number of 7.0 and 6.0 doses of 
bevacizumab, respectively. Cohorts 2 and 4 were given a 
median number of 66.5 and 87.0 doses of daily motesanib, 
respectively. Demographic and baseline characteristics 
are depicted in Table 1. Patients’ duration of study 
participation is provided in Figure 1 of the Supplemental 
Data section.
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Table 1: Demographic and disease characteristics
Cohort 1 Cohort 3 Cohort 2 Cohort 4 Cohorts 1–4
Trebananib 
3 mg kg−1 + 
bevacizumab 
15 mg kg−1 
(n = 6)
Trebananib 
10 mg kg−1 + 
bevacizumab 
15 mg kg−1 
(n = 19)
Trebananib 
3 mg kg−1 + 
motesanib 75 mg 
(n = 8)
Trebananib 3 mg 
kg−1 + motesanib 
125 mg (n = 3)
Trebananib + 
bevacizumab 
or motesanib 
(n = 36)
Sex, n (%)
 Female 2 (33) 13 (68) 4 (50) 2 (67) 21 (58)
 Male 4 (67) 6 (32) 4 (50) 1 (33) 15 (42)
Race/ethnicity, n (%)
 Caucasian 5 (83) 14 (74) 8 (100) 3 (100) 30 (83)
 African American 0 (0) 3 (16) 0 (0) 0 (0) 3 (8)
 Hispanic 1 (17) 1 (5) 0 (0) 0 (0) 2 (6)
 Asian 0 (0) 1 (5) 0 (0) 0 (0) 1 (3)
Age, median (range), years 61.5 (33, 73) 56 (38, 73) 53.5 (37, 80) 55 (51, 67) 56 (33, 80)
ECOG score, n (%)
 0 2 (33) 7 (37) 3 (38) 2 (67) 14 (39)
 1 4 (67) 11 (58) 5 (63) 1 (33) 21 (58)
 2 0 (0) 1 (5) 0 (0) 0 (0) 1 (3)
Primary tumour type, n (%)
 Breast cancer 1 (17) 8 (42) 0 (0) 0 (0) 9 (25)
 Prostate cancer 1 (17) 3 (16) 0 (0) 0 (0) 4 (11)
 Uterine cancer 1 (17) 2 (11) 1 (13) 0 (0) 4 (11)
 Ovarian cancer 0 (0) 0 (0) 2 (25) 2 (67) 4 (11)
  Head and neck squamous 
cell cancer 1 (17) 1 (5) 0 (0) 0 (0) 2 (6)
 Oesophageal cancer 0 (0) 0 (0) 2 (25) 0 (0) 2 (6)
 Pancreatic cancer 1 (17) 1 (5) 0 (0) 0 (0) 2 (6)
 Small cell lung cancer 1 (17) 0 (0) 1 (13) 0 (0) 2 (6)
 Testicular cancer 0 (0) 0 (0) 1 (13) 0 (0) 1 (3)
 Ureteral cancer 0 (0) 0 (0) 1 (13) 0 (0) 1 (3)
 Melanoma 0 (0) 1 (5) 0 (0) 0 (0) 1 (3)
 Non-small cell lung cancer 0 (0) 1 (5) 0 (0) 0 (0) 1 (3)
 Soft-tissue sarcoma 0 (0) 1 (5) 0 (0) 0 (0) 1 (3)
 Other 0 (0) 1 (5) 0 (0) 1 (33) 2 (6)
Lines of prior chemotherapy, n (%)
 0 0 (0 ) 1 (5) 0 (0) 0 (0) 1 (3)
 1 0 (0) 2 (11) 1 (13) 0 (0) 3 (8)
 2 2 (33) 2 (11) 2 (25) 1 (33) 7 (19)
 ≥3 4 (67) 14 (74) 5 (63) 2 (67) 25 (69)
Any prior radiotherapy, n (%)
Yes 5 (83) 12 (63) 2 (25) 0 (0) 19 (53)
No 1 (17) 7 (37) 6 (75) 3 (100) 17 (47)
Any prior cancer-related surgery, n (%)
Yes 5 (83) 17 (89) 7 (88) 3 (100) 32 (89)
No 1 (17) 2 (11) 1 (13) 0 (0) 4 (11)
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Figure 1: Pharmacokinetic concentration-time profiles. (A) mean (+ SD) serum concentration-time profiles of trebananib at week 
4 after 3 mg kg−1 IV QW infusions of trebananib in combination with motesanib and after 3 and 10 mg kg−1 IV QW infusions of trebananib 
with bevacizumab. (B) mean (+ SD) plasma concentration-time profiles of motesanib after 75 or 125 mg oral QD dosing of motesanib in 
combination with trebananib 3 mg kg−1.
Tolerability
No DLTs occurred in cohort 1 (trebananib 3 mg kg−1 
plus bevacizumab 15 mg kg−1). Nonetheless, after one 
of the initial three enrolled patients died from arterial 
haemorrhage at week 10, the decision was made to 
expand the current cohort to six patients before initiating 
enrolment into the higher dose cohort (cohort 3). One 
patient in cohort 2 (trebananib 3 mg kg−1 plus motesanib 
75 mg) had a DLT of intestinal perforation; therefore, 
cohort 2 was also expanded to include six patients. 
Two patients in cohort 2 did not receive trebananib and 
motesanib simultaneously during the first study month 
on days when both therapies were administered; thus, 
two new patients were added for a total of eight patients. 
In cohort 3 (trebananib 10 mg kg−1 plus bevacizumab 
15 mg kg−1), one patient had a DLT of tumour 
haemorrhage. No DLTs occurred in cohort 4 (trebananib 
3 mg kg−1 plus motesanib 125 mg). Five patients in cohort 
3 received fewer than three doses of trebananib as the 
result of a DLT (n = 1) and disease progression (n = 4); 
thus, the cohort was expanded to include an additional 
three patients. Investigators opted to add 10 more patients 
to cohort 3 for a final cohort enrolment of 19 patients.
This report presents treatment-related adverse events 
that were considered to be possibly related to any of the 
administered study agents per the clinical investigator’s 
assessment. No cohort-specific trends in the incidence of 
treatment-related adverse events across treatment groups 
were noted. Across the dose cohorts of trebananib plus 
bevacizumab (cohorts 1 and 3, n = 25), the most common 
treatment-related adverse events included fatigue, 
diarrhoea, constipation, nausea, and epistaxis (Table 2). 
Three patients (12%) had grade ≥3 treatment-related 
adverse events, including arterial haemorrhage (grade 
5; n = 1) in a patient with squamous cell head and neck 
Oncotarget11158www.impactjournals.com/oncotarget
cancer in cohort 1, tumour haemorrhage (grade 5; n = 1) 
in a patient with squamous cell head and neck cancer, and 
fatigue (grade 3; n = 1) in a patient with breast cancer 
in cohort 3. No grade 4 treatment-related adverse events 
occurred in cohorts 1 or 3. In addition to the patients with 
arterial haemorrhage and tumour haemorrhage in cohorts 
1 and 3, respectively, two patients in cohort 3 died from 
disease progression (n = 1) and respiratory failure (n = 1). 
Those two deaths were not considered to be related to the 
study treatment.
Across the dose cohorts of trebananib plus 
motesanib (cohorts 2 and 4, n = 11), the most common 
treatment-related adverse events included hypertension, 
diarrhoea, nausea, fatigue, vomiting, and decreased 
appetite (Table 3). Two patients (18%) had grade ≥ 3 
treatment-related adverse events; those events were all 
grade 3 and included hypertension (n = 1) in a patient 
with ovarian cancer, and leukoencephalopathy (n = 1) 
(the patient with leukoencephalopathy was not on 
antihypertensive medication previously) and intestinal 
perforation (n = 1) in a patient with ureteral cancer; the 
events of hypertension and leukoencephalopathy were 
not considered to be related to trebananib treatment. No 
grade 4 treatment-related adverse events occurred. Two 
patients died from renal failure (n = 1) and respiratory 
failure (n = 1), which was not considered to be treatment-
related.
Pharmacokinetics
The mean (+SD) serum concentration-time 
profiles of trebananib at steady state at week 4 following 
weekly IV infusions of trebananib in combination with 
bevacizumab or motesanib are shown in Figure 1A. Values 
for PK parameters of trebananib in this study are listed in 
Table 4 and are similar to those reported for trebananib 
monotherapy in a phase 1 study [16], consistent with a 
lack of effect of bevacizumab or motesanib on trebananib 
PK. Only limited data (n = 3) was available for cohort 4. 
The mean plasma concentration profiles of motesanib at 
75 mg or 125 mg when coadministered with trebananib 
3 mg kg−1 were similar to their profiles observed without 
the addition of trebananib (Table 4; Figure 1B).
Immunogenicity
Serum samples for anti-trebananib antibody analyses 
were available for all 36 patients. In both cohorts 1 and 3 
(trebananib plus bevacizumab), one patient each developed 
binding antibodies during study treatment. Both patients 
continued to test positive for binding antibodies at the 
end of the study. One patient in cohort 2 was transiently 
positive for binding antibodies. No binding antibodies 
were detected in cohort 4. The baseline samples for one 
patient in cohort 1 and two patients in cohort 2 neutralised 
the trebananib activities in the neutralising activity assay, 
but did not demonstrate positivity in the immunoassay. 
Therefore, it was concluded that the samples did not have 
neutralising antibodies. No patient developed neutralising 
antibodies during the study period.
Biomarkers
Changes in biomarker levels during treatment 
relative to baseline were statistically significant for two of 
the five tested analytes. There was a nominally significant 
increase in serum levels of PLGF in each cohort, except 
in cohort 4 (P-values ranged from 0.03 to 0.12 across 
timepoints; Supplemental Data, Figure 2A), which may 
be related to the limited number of available patient 
data (n = 3) for that cohort. Increases in serum levels of 
sVCAM-1 during treatment compared with baseline were 
statistically significant in each cohort (Supplemental Data, 
Figure 2B). Closer examination reveals a steplike pattern 
with an initial increase of sVCAM-1 levels on treatment 
day 4 followed by another elevation on day 9. In cohort 
2, sVCAM-1 returned to pretreatment levels on day 50.
sKit was significantly (P < 0.01) elevated in cohort 3 
on days 2 and 4. The remaining analytes remained largely 
unchanged over time for any of the treatment cohorts 
(data not shown). VEGF levels for either dose cohort of 
trebananib plus bevacizumab could not be detected as the 
result of assay interference from bevacizumab. There were 
no correlations between any of the biomarkers and tumour 
response (data not shown).
Tumour response
All patients who received ≥1 dose of trebananib 
(n = 36) were initially considered for tumour response 
assessment. Tumour response by RECIST 1.0 [24] was 
available for 26 patients (Figure 2).
In the trebananib plus bevacizumab arms (cohorts 1 
and 3), 25 patients received ≥1 dose of trebananib. 
Of these, 18 patients had response measurements by 
RECIST. Postbaseline tumour response assessments were 
not conducted for seven patients due to rapid clinical 
progression (n = 4), death (n = 1), and incorrect imaging 
(n = 2). Across cohorts 1 and 3, no patient achieved a 
complete response; two patients had a confirmed partial 
response. One of the patients with a partial response was 
in cohort 1 and had prostate cancer (duration of response, 
16.3 weeks); the other patient was in cohort 3 and had 
breast cancer (duration of response, 68.1 weeks; this 
patient did not develop progressive disease by the data 
analysis cutoff date). The median percent change in 
tumour size was −1.23% across cohorts 1 and 3. Eleven 
patients had stable disease by RECIST criteria as their 
best response. Five patients with prostate (n = 2), thyroid 
(n = 1), breast (n = 1), and pancreatic cancer (n = 1) had 
stable disease >6 months (range: 28.6–84.1 weeks) while 
receiving study treatment.
In the trebananib plus motesanib arms (cohorts 
2 and 4), 11 patients were evaluable. Eight patients 
Oncotarget11159www.impactjournals.com/oncotarget
Table 2: Patient incidence of treatment–related adverse events in the trebananib plus bevacizumab 
cohorts
Cohort 1 Cohort 3 Cohorts 1–3
Trebananib 3 mg kg−1 + 
bevacizumab 15 mg kg−1 (n = 6)
Trebananib 10 mg kg−1 + 
bevacizumab 15 mg kg−1 (n = 19)
Trebananib + 
bevacizumab (n = 25)
Patients with any 
treatment-related 
adverse eventa, n (%)
5 (83) 10 (53) 15 (60)
Grade 3 0 (0) 1 (5) 1 (4)
Grade 4 0 (0) 0 (0) 0 (0)
Grade 5 1 (17)b 1 (5)c 2 (8)
Treatment-related 
adverse events occurring 
in one or more treatment 
arms, n (%)
All grades Grade ≥ 3 All grades Grade ≥ 3 All grades Grade ≥ 3
Fatigue 3 (50) 0 (0) 5 (26) 1 (5) 8 (32) 1 (4)
Diarrhoea 1 (17) 0 (0) 3 (16) 0 (0) 4 (16) 0 (0)
Constipation 0 (0) 0 (0) 3 (16) 0 (0) 3 (12) 0 (0)
Nausea 1 (17) 0 (0) 2 (11) 0 (0) 3 (12) 0 (0)
Epistaxis 2 (33) 0 (0) 1 (5) 0 (0) 3 (12) 0 (0)
Chest discomfort 1 (17) 0 (0) 1 (5) 0 (0) 2 (8) 0 (0)
Arthralgia 1 (17) 0 (0) 1 (5) 0 (0) 2 (8) 0 (0)
Cough 0 (0) 0 (0) 2 (11) 0 (0) 2 (8) 0 (0)
Hypertension 0 (0) 0 (0) 2 (11) 0 (0) 2 (8) 0 (0)
Arterial haemorrhage 1 (17) 1 (17) 0 (0) 0 (0) 1 (4) 1 (4)
Tumour haemorrhage 0 (0) 0 (0) 1 (5) 1 (5) 1 (4) 1 (4)
Myopia 0 (0) 0 (0) 1 (5) 0 (0) 1 (4) 0 (0)
Lower abdominal pain 0 (0) 0 (0) 1 (5) 0 (0) 1 (4) 0 (0)
Vomiting 0 (0) 0 (0) 1 (5) 0 (0) 1 (4) 0 (0)
Chest pain 1 (17) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
Mucosal inflammation 0 (0) 0 (0) 1 (5) 0 (0) 1 (4) 0 (0)
Laryngitis 1 (17) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
Groin pain 0 (0) 0 (0) 1 (5) 0 (0) 1 (4) 0 (0)
Headache 0 (0) 0 (0) 1 (5) 0 (0) 1 (4) 0 (0)
Exertional dyspnoea 0 (0) 0 (0) 1 (5) 0 (0) 1 (4) 0 (0)
Oropharyngeal pain 1 (17) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
Pleuritic pain 1 (17) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
Throat irritation 1 (17) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
Rash 0 (0) 0 (0) 1 (5) 0 (0) 1 (4) 0 (0)
Macular rash 1 (17) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
Decreased weight 1 (17) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
aTreatment-related adverse events include all treatment-emergent adverse events that had a reasonable possibility of being 
related to trebananib or bevacizumab therapy; all patients received ≥1 dose of trebananib.
bTreatment-related adverse event was arterial haemorrhage in a patient with squamous cell carcinoma.
cTreatment-related adverse event was a DLT of tumour haemorrhage in a patient with squamous cell carcinoma.
Oncotarget11160www.impactjournals.com/oncotarget
Table 3: Patient incidence of treatment–related adverse events in the trebananib plus motesanib 
cohorts
Cohort 2 Cohort 4 Cohorts 2–4
Trebananib 3 mg kg−1 + 
motesanib 75 mg (n = 8)
Trebananib 3 mg kg−1 + 
motesanib 125 mg (n = 3)
Trebananib + 
motesanib (n = 11)
Patients with any treatment-
related adverse eventa, n (%) 7 (88) 2 (67) 9 (82)
Grade 3 2 (25)b 0 (0) 2 (18)
Grade 4 0 (0) 0 (0) 0 (0)
Grade 5 0 (0) 0 (0) 0 (0)
Treatment-related adverse 
events occurring in one or 
more treatment arms, n (%)
All grades Grade ≥ 3 All grades Grade ≥ 3 All grades Grade ≥ 3
Hypertension 3 (38) 1 (13) 1 (33) 0 (0) 4 (36) 1 (9)
Diarrhoea 3 (38) 0 (0) 1 (33) 0 (0) 4 (36) 0 (0)
Nausea 2 (25) 0 (0) 1 (33) 0 (0) 3 (27) 0 (0)
Fatigue 3 (38) 0 (0) 0 (0) 0 (0) 3 (27) 0 (0)
Vomiting 1 (13) 0 (0) 1 (33) 0 (0) 2 (18) 0 (0)
Decreased appetite 1 (13) 0 (0) 1 (33) 0 (0) 2 (18) 0 (0)
Hypothyroidism 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Blurred vision 0 (0) 0 (0) 1 (33) 0 (0) 1 (9) 0 (0)
Abdominal pain 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Lower abdominal pain 0 (0) 0 (0) 1 (33) 0 (0) 1 (9) 0 (0)
Cheilitis 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Gastro-oesophageal reflux 
disease 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Intestinal perforationc 1 (13) 1 (13) 0 (0) 0 (0) 1 (9) 1 (9)
Early satiety 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Noncardiac chest pain 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Peripheral oedema 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Increased alanine 
aminotransferase 0 (0) 0 (0) 1 (33) 0 (0) 1 (9) 0 (0)
Hypomagnesaemia 0 (0) 0 (0) 1 (33) 0 (0) 1 (9) 0 (0)
Arthralgia 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Myalgia 0 (0) 0 (0) 1 (33) 0 (0) 1 (9) 0 (0)
Tumour pain 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
Headache 0 (0) 0 (0) 1 (33) 0 (0) 1 (9) 0 (0)
Leukoencephalopathy 1 (13) 1 (13) 0 (0) 0 (0) 1 (9) 1 (9)
Urinary bladder haemorrhage 0 (0) 0 (0) 1 (33) 0 (0) 1 (9) 0 (0)
Sexual dysfunction 0 (0) 0 (0) 1 (33) 0 (0) 1 (9) 0 (0)
Rash 1 (13) 0 (0) 0 (0) 0 (0) 1 (9) 0 (0)
aTreatment-related adverse events include all treatment-emergent adverse events that had a reasonable possibility of being 
related to trebananib or motesanib therapy; all patients received ≥ 1 dose of trebananib.
bOne patient had two grade 3 adverse events (intestinal perforation, leukoencephalopathy).
cIntestinal perforation for this patient was rated as a grade 3 treatment-related adverse event and classified as a DLT.
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Table 4: Summary of Trebananib Pharmacokinetic Parameters
Trebananib 3 mg kg−1 Trebananib 10 mg kg−1 Motesanib 75 mg Motesanib 125 mg
Descriptive 
statistics
Bev 
15 mg 
kg−1
Mot 
75 mg
Mot 
125 mg Bev 15 mg kg
−1 Without 
Trebananib
Trebananib 
3 mg kg−1
Without 
Trebananib
Trebananib 
3 mg kg−1
Tmax (h)a
 N 6 6 3 14 9 5 3 2
 Mean 0.55 0.57 0.53 0.50 1.1 1.0 1.0 1.0
 %CV 6.1 160 12 11 100 200 37 NA
Cmax (µg ml−1)b
 N 6 6 3 14 9 5 3 2
 Mean 69.6 82.0 78.1 421 0.466 0.507 0.559 0.541
 %CV 15.0 160 22 143 75.9 40.6 53.2 NA
AUCtou (µg·h ml−1)c
 N 6 6 3 14 9 5 3 2
 Mean 2930 3230 2200 9040 2.58 3.18 3.13 3.92
 %CV 24.5 26.5 21.0 32.0 68.1 89.7 12.2 NA
CL (ml h−1 kg−1) C24 (µg ml−1)
 N 6 6 3 14 9 3 3 2
 Mean 0.873 0.747 1.22 1.03 20.9 173 14.2 78.7
 %CV 26.5 42.1 21.3 33.9 79.6 159 50.7 NA
aTmax = Time to reach Cmax; reported as median and range
bCmax = Maximum observed concentration during a dosing interval
cAUC = Area under the concentration-time curve from time 0 to 168 hours for trebananib and time 0 to 24 hours for motesanib
AUCtou = Area under the concentration-time curve in a dosing interval at steady state;
Abbreviations: Bev = bevacizumab; CL = Clearance; C24 = concentration 24 hours after the start of infusion; 
Mot = motesanib; NA = Not applicable; CV = coefficient of variation.
Figure 2: Tumour response by RECIST 1.0. Maximum percent change (measured by sum of longest diameters) in tumour burden 
by tumour type for each patient and study week when maximum percent change in tumour burden for each patient occurred.
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had response measurements by RECIST. Postbaseline 
tumour responses could not be evaluated for three 
patients as the result of withdrawal of consent (n = 2) and 
clinical progression (n = 1). One patient with testicular 
cancer achieved a confirmed partial response that lasted 
85.0 weeks (Supplemental Data, Figures 3A & B); the 
patient remained on the study for 116 weeks. The median 
percent change in tumour size was −15.06% across cohorts 
2 and 4. Five patients with ovarian (n = 3), adrenal cortical 
(n  = 1), and uterine cancer (n = 1) had stable disease by 
RECIST criteria, with the response of one patient with 
ovarian cancer lasting >6 months (41.0 weeks).
DISCUSSION
The current study of trebananib administered 
intravenously QW in combination with bevacizumab 
or motesanib in patients with advanced cancer with 
considerable pre-treatment (69% of patients had received 
≥3 lines of prior chemotherapy), shows that with both 
combinations, a true maximum tolerated dose was not 
achieved. Overall, the adverse events were similar to 
those toxicities described for trebananib, bevacizumab, 
and motesanib alone [16, 21, 22, 28]. Previous studies 
have demonstrated that the combination of two VEGF 
pathway inhibitors is generally not well tolerated in 
patients with cancer [29, 30]. In this study, it appeared 
that a less severe toxicity profile was associated with the 
combination of trebananib plus bevacizumab or motesanib 
when compared with toxicity profiles typically associated 
with treatments combining two VEGF pathway inhibitors.
One DLT occurred in cohort 3 when trebananib 
was combined with bevacizumab, and two deaths were 
thought to be at least possibly related to both trebananib 
and bevacizumab treatment per the clinical investigator’s 
assessment. Those deaths occurred in head and neck cancer 
patients with squamous cell pathology and extensive 
disease to the lung and neck. One of those two patients 
developed severe neck pain and a new mass on the left 
neck 5 days after the first study drug dosing; 4 days later, 
the patient died with haemorrhage from the mouth. The 
second patient developed a massive haemorrhage from the 
mouth and nose and died after eight doses of trebananib 
and three doses of bevacizumab. In both instances, 
patients had tumours with squamous cell pathology, which 
at the start of the study was not an exclusion criterion for 
the treatment combination. Extensive experience with 
bevacizumab has shown that patients with squamous cell 
lung cancer are at high risk for tumour bleeding (31%) 
with fatal or serious bleeding events [31], which has led 
to a warning against using bevacizumab in squamous cell 
lung cancer [32]. Similarly, a study with bevacizumab 
and pemetrexed in recurrent or metastatic squamous 
cell head and neck cancer showed a high rate (15%) of 
grade 3 to 5 bleeding events [33]. It is unclear as to how 
much trebananib contributed to the deaths in the current 
study. The most common treatment-related adverse events 
seen with the trebananib plus bevacizumab combination 
included fatigue (32%), diarrhoea (16%), constipation 
(12%), nausea (12%), and epistaxis (12%). Of the 
25 patients who received the combination, 12% had grade 
≥ 3 treatment-related adverse events. There appeared to 
be no noticeable increase in hypertension, proteinuria, or 
intestinal perforation beyond what would be expected with 
bevacizumab alone.
Both trebananib [17] and bevacizumab [34] 
are likely active as single agents in combination with 
chemotherapy and, therefore, their combination has a 
potential risk of increasing the frequency or severity of 
toxicities that are typically observed during trebananib or 
bevacizumab monotherapy, such as peripheral oedema for 
trebananib [16] or intestinal perforation for bevacizumab 
[35]. All four patients with ovarian cancer who were 
enrolled in our study received trebananib plus motesanib 
and did not experience any signs of intestinal perforation, 
with three of the four patients having some level of 
minor response. Although we did not enrol any patients 
with ovarian cancer in the trebananib plus bevacizumab 
arms, the lack of intestinal perforation in the patients with 
ovarian cancer in the trebananib plus motesanib arms 
may suggest that combining trebananib and bevacizumab 
does not have a high incidence of intestinal perforation 
in a population with ovarian cancer. In addition, Karlan 
et al [17] showed recently that treatment with trebananib 
in combination with paclitaxel was not associated with 
a higher incidence of intestinal perforations in patients 
with recurrent ovarian cancer relative to a placebo group. 
This finding suggests that a combination of trebananib 
and bevacizumab may be feasible without significantly 
increasing the intestinal perforation rate over bevacizumab 
alone. A dose-response effect was also reported in the 
study by Karlan and colleagues, with improvement of 
PFS at trebananib 10 mg kg−1 (PFS, 2.6 months) versus 
trebananib 3 mg kg−1 (PFS, 1.1 months). In our study, we 
showed that trebananib plus bevacizumab was tolerable 
at doses up to 10 mg kg−1 for trebananib and 15 mg kg−1 
for bevacizumab. Higher doses may be achievable with 
trebananib at 15 mg kg−1 and bevacizumab at 15 mg kg−1 
given the lack of synergistic toxicities seen at the current 
tested dose levels.
The most common treatment-related adverse events 
associated with the trebananib and motesanib combination 
included hypertension (36%), diarrhoea (36%), nausea 
(27%), fatigue (27%), vomiting (18%), and decreased 
appetite (18%). These findings are similar to the adverse 
events seen with motesanib alone. The common toxicities 
previously associated with trebananib monotherapy, such 
as peripheral oedema, were not seen in this combination 
and may be reflective of the lower dose of trebananib at 
3 mg kg−1 administered in the motesanib combination 
cohorts. The lack of haematologic adverse events that are 
typically observed with other combinations of VEGFR 
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tyrosine kinase inhibitors and VEGFR axis antibodies, 
such as bevacizumab plus sorafenib [2] or bevacizumab 
plus sunitinib [36], was encouraging. Patients received 
trebananib a median of 9.5 and 11.0 weeks in cohorts 2 
and 4, respectively; motesanib was administered a median 
of 67 and 87 days in those corresponding cohorts. One 
limitation of the design of this trial with a standard 3+3 
design was the short DLT window (28 days), which did 
not adequately assess for long–term ongoing toxicities 
such as grade 2 nausea.
Although assessment of efficacy was not a primary 
objective of the study, the combinations showed some 
interesting clinical activity. In cohort 3, a prostate cancer 
patient with significant lung and bone metastases had a 
partial response despite an increase in this patient’s prostate–
specific antigen (data not shown). A second patient with 
breast cancer in cohort 3 had a partial response lasting 68 
weeks. In addition, a patient with testicular cancer in cohort 
2 showed a partial response lasting 85 weeks. Finally, six 
patients had stable disease lasting >6 months while on study; 
they were two patients with prostate cancer, and one patient 
each with ovarian, thyroid, breast, or pancreatic cancer.
The PK of motesanib did not appear to be affected 
when administered in combination with trebananib. In 
addition, trebananib concentration-time profiles in this 
study were comparable to those of the monotherapy trial 
[16], suggesting that trebananib PK was not affected by 
the coadministration of bevacizumab or motesanib. The 
presence of the binding anti-drug antibodies did not appear 
to affect the PK of trebananib.
We explored five potential biomarkers of 
angiogenesis to measure the biological activity of 
the trebananib combinations. Only serum PLGF and 
sVCAM-1 showed significant increases in each cohort. In 
a combination study of trebananib with chemotherapy, a 
rise in PLGF and sVCAM-1 concentrations in each cohort 
(trebananib plus FOLFOX-4, carboplatin/paclitaxel, or 
docetaxel) was also observed [37]. Other antiangiogenic 
agents, such as sunitinib [38, 39], bevacizumab [40], and 
motesanib [21], have shown increases in PLGF, which may 
reflect a compensatory mechanism (ie, increase in upstream 
proangiogenic signalling) when blocking downstream 
pathways. Based on our data, there is not a significant 
difference in changes in PLGF and sVCAM-1 between the 
high and low dose levels of trebananib, except during week 
50 for sVCAM-1. However, the number of samples in our 
study was small, and a larger cohort is needed to come to a 
definitive conclusion whether trebananib dose levels affect 
PLGF or sVCAM-1 changes during treatment.
In conclusion, the combination of VEGF pathway 
inhibitors in the treatment of cancer has been previously 
associated with high toxicity. In this study, results suggest 
that the combinations of trebananib, an angiopoietin 
pathway inhibitor, with the anti-VEGF agents 
bevacizumab or motesanib in patients with advanced solid 
tumours may be associated with a less severe toxicity 
profile when compared with combination treatments 
targeting only the VEGF pathway. Furthermore, the 
combinations tested in the present study did not appear 
to exacerbate toxicities that are typically observed when 
these treatments are administered as monotherapies. 
Although the trial did not show clear evidence of 
synergistic activity, the treatment combinations were 
associated with antitumour activity across a broad range 
of tumour types. The data support larger studies of 
trebananib in combination with VEGF pathway inhibitors. 
Various phase 2 clinical trials have been conducted, 
including studies of trebananib with sorafenib in patients 
with advanced hepatocellular carcinoma (ClinicalTrials.
gov NCT00872014), trebananib with sunitinib [41] or 
sorafenib [42] in patients with renal cell cancer, and 
trebananib with bevacizumab in patients with breast 
cancer (ClinicalTrials.gov NCT00511459).
MATERIALS AND METHODS
Patients
Key eligibility criteria included age ≥18 years; a 
diagnosis of advanced solid tumors refractory to standard 
treatment; measurable or evaluable (nonmeasurable) 
disease per Response Evaluation Criteria in Solid Tumors 
(RECIST) guidelines (v.1.0) [24]; an Eastern Cooperative 
Oncology Group (ECOG) performance status ≤2; and 
adequate hematological, renal, and hepatic function. 
Excluded were patients with a prior bleeding diathesis, 
gastrointestinal surgery or disease, thrombosis or 
pulmonary embolism or cardiovascular events during the 
past year; a diagnosis of ovarian cancer while receiving 
bevacizumab; a diagnosis of lung cancer with tumor 
lesions ≥3 cm; or chronic uncontrolled hypertension, 
chronic hepatitis, or symptomatic or untreated central 
nervous system metastases; a treatment history with 
angiopoietin or VEGF inhibitors or radiation therapy 
to the abdomen; recent treatment with anticancer or 
palliative radiation; or current treatment regimens 
containing strong CYP 3A inhibitors, immune modulators, 
St. John’s wort, or coumarin anticoagulants ≥2 mg/day. 
Because two patients with squamous cell head and neck 
cancer developed grade 5 hemorrhage, the protocol was 
amended to exclude patients with head and neck cancer or 
lung squamous cell tumors. All patients provided written 
informed consent. An institutional review board of each 
study center approved all study procedures.
Study design and treatment
This open-label, dose escalation phase 1b study was 
carried out at five centres in the United States and examined 
trebananib in combination with bevacizumab, motesanib, 
sorafenib, or sunitinib (Supplemental Data, Figure 4). 
Patients in the cohorts receiving trebananib combined 
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with bevacizumab or motesanib had diagnoses of advanced 
solid tumours across various tumour types. In contrast, 
patients in the cohorts receiving trebananib combined 
with sorafenib or sunitinib had primary diagnoses of renal 
cell cancer. To avoid invalid comparisons between those 
two patient groups, only findings from cohorts receiving 
trebananib combined with bevacizumab or motesanib 
are presented in the current report. Those cohorts 
were cohort 1 (trebananib 3 mg kg−1 + bevacizumab 
15 mg kg−1), cohort 2 (trebananib 3 mg kg−1 + motesanib 
75 mg), cohort 3 (trebananib 10 mg kg−1 + bevacizumab 
15 mg kg−1), and cohort 4 (trebananib 3 mg kg−1 + 
motesanib 125 mg). Trebananib and bevacizumab were 
administered intravenously QW and once every 3 weeks 
(Q3W), respectively; motesanib was self-administered 
orally by patients once daily (QD). For each cohort, 
trebananib was initiated on day 1 of the second week; the 
first dose of bevacizumab or motesanib was administered 
on day 1 of the first week. For patients in cohorts 1 and 3, 
trebananib was administered at least 30 minutes following 
bevacizumab infusion on days when both therapies were 
administered; for patients in cohorts 2 and 4, trebananib 
and motesanib had to be administered simultaneously. 
Trebananib dose levels were selected based on the first-
in-human monotherapy study showing trebananib up to 
30 mg kg−1 to be tolerable [16]. The study protocol was 
amended to remove trebananib 30 mg/kg, consistent with 
dosing in a planned phase 2 study. Tolerable dose levels of 
bevacizumab and motesanib were established upon review 
of completed clinical trials [21, 25].
An initial three patients entered cohort 1 
(trebananib plus bevacizumab) and cohort 2 (trebananib 
plus motesanib). If none of the initial three patients 
experienced a dose-limiting toxicity (DLT) in cohort 
1 or 2, up to six patients were enrolled to receive a 
higher dose (10 mg kg−1) of trebananib with the same 
dose (15 mg kg−1) of bevacizumab in cohort 3 and 
the same dose (3 mg kg−1) of trebananib with a higher 
dose (125 mg) of motesanib in cohort 4. If one of the 
initial three patients in cohort 1 or 2 experienced a 
DLT, that cohort was expanded to six patients. In this 
expanded cohort 1 or 2, if fewer than three patients 
experienced a DLT, up to six patients were enrolled 
into the corresponding higher dose cohort 3 or 4. If 
two or more of the initial three patients in cohort 1 or 2 
experienced a DLT, no additional patients were enrolled 
into the respective higher dose cohorts. A maximum of 10 
additional patients could be added to one cohort of each 
treatment combination (trebananib plus bevacizumab and 
trebananib plus motesanib), irrespective of dosage. Since 
patients received only bevacizumab or motesanib for the 
first study week before trebananib dosing was initiated, 
any patient who experienced a DLT during the first study 
week was withdrawn and replaced with a new patient. 
Patients who discontinued the study during the first study 
month were also withdrawn and replaced. DLTs occurring 
during the first study week did not influence the dose 
escalation process. For any patient in a given cohort who 
experienced a treatment deviation with trebananib during 
the first study month, an additional patient was enrolled.
A DLT was any related, grade 3 or higher 
haematologic or nonhaematologic toxicity during the 
initial 28 study days, except for the following adjustments 
(which were required for those AEs to be considered dose 
limiting): transient grade 3 infusion reactions lasting more 
than 2 hours; grade 3 fatigue for more than 7 days; grade 
3 or 4 nausea, diarrhoea, or vomiting despite maximum 
supportive care; grade 3 or 4 neutropenia with fever above 
38.5°C; grade 4 neutropenia for more than 7 days; grade 
4 thrombocytopenia, anaemia, and hypertension; grade 4 
aspartate or alanine aminotransferase greater than 10 times 
the upper limit of normal.
Primary endpoints were the incidence of adverse 
events and PK of trebananib and motesanib. Secondary 
endpoints were anti–trebananib antibody formation, the 
biomarker profile, and tumor response.
Blood pressure monitoring. Patients’ blood pressure 
was measured based on the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure (JNC 7). All 
measurements were conducted on site and according to the 
following guidelines: caffeine, exercise, and smoking were 
avoided for at least 30 minutes before the measurement; 
patients should be seated for at least 5 minutes in a chair 
(rather than on an examination table), with feet on the 
floor, and arm supported at the heart level; an appropriately 
sized cuff (cuff bladder encircling at least 80% of the 
arm) was used to ensure accuracy. Blood pressure was 
measured according to the following schedule: screening, 
weeks 1 and 5 (predose, 1, 4, and 24 hours postdose); 
weeks 2, 3, 4, 6, and beyond (predose); end of study visit.
Adverse events
Adverse events were recorded and classified 
following the Medical Dictionary for Regulatory 
Activities and subsequently graded according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI-CTCAE v.3.0). Adverse events 
were determined by clinical evaluations and laboratory 
assessments at screening and on the first day of every 
study week. Unless otherwise noted, this report presents 
treatment-related adverse events as assessed by the clinical 
investigator based on a reasonable possibility that the 
event could be related to any of the study treatments. All 
patients who received ≥1 dose of any study agent were 
included in this analysis set.
Pharmacokinetics
Motesanib PK was assessed by comparing 
week 1 versus week 4 or 5 (motesanib without and 
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with trebananib, respectively). Serum samples for the 
evaluation of minimum and maximum observed trebananib 
concentrations in the plasma were collected immediately 
before dosing on day 1 of weeks 2, 3, 4, 5, 6, 8, and every 
8 weeks thereafter until 4 weeks after the last dose of study 
treatment. In addition, intensive sampling was conducted 
at the end of infusion, and 6, 24, 48, and 96 hours 
following dosing on day 1 of weeks 4 or 5. The samples 
were analysed for trebananib concentrations employing a 
validated enzyme-linked immunosorbent assay [16].
Assessment of bevacizumab PK interaction 
with trebananib was not feasible due to bevacizumab 
accumulation between weeks 1 and 5. For motesanib, 
postdose samples were taken at 0.5, 1, 4, 6, and 24 hours 
during weeks 1 and 5 (without and with trebananib 
coadministration, respectively). Motesanib plasma 
concentrations were assessed with a validated liquid 
chromatography/mass spectrometry (LC-MS/MS) method 
at Cedra Corporation (Austin, TX).
Immunogenicity
Serum samples were evaluated for immunogenicity 
of trebananib prior to dosing during weeks 1, 3, 5, 8, and 
every 4 weeks thereafter until study termination. Two 
validated assays, an electrochemiluminescence (ECL) 
immunoassay and ECL receptor-binding neutralising 
assay, were used to detect anti-trebananib binding and 
neutralizing antibodies, respectively [26]. A sample was 
defined as positive for neutralizing antibodies when it 
was positive for binding antibodies in the immunoassay 
and positive in the neutralizing activity assay.
Biomarkers
Pharmacodynamic profiles of biomarkers were 
evaluated in serum samples obtained immediately before 
and 24 and 72 hours after dosing during weeks 1 and 2 
and before dosing during weeks 3, 4, and 8 and every 
8 weeks thereafter until the last study visit. Specific 
biomarkers assessed included angiogenic cytokines 
(VEGF, placental growth factor [PLGF]), soluble 
VEGFR-2, soluble c-Kit receptor (sKit), and soluble 
vascular cell adhesion molecule-1 (sVCAM-1). To 
quantify PLGF and VEGF levels, a three-plex sandwich 
immunoassay with electrochemiluminescent detection 
(Meso-Scale Discoveries [MSD], Gaithersburg, MD]) 
was used. VEGFR-2 and sKit levels were measured with 
a two-plex MSD assay. sVCAM-1 levels were quantified 
using specific ELISA kits (R&D Systems, Minneapolis, 
MN). All biomarker measurements were conducted as 
previously described [27]. The detection of VEGF was 
completely inhibited when bevacizumab was added to 
samples during assay validation. Therefore, VEGF results 
are not reported for cohorts 1 and 3.
Tumour response evaluations
Computerized tomography (CT) or magnetic 
resonance imaging (MRI) assessment of measureable 
disease was conducted within a 4–week time window 
before treatment initiation and extended to 8 weeks for 
brain imaging. Tumour response was evaluated with 
CT or MRI at week 8 and every 8 weeks thereafter and 
categorized using RECIST, version 1.0 [24]. Patients who 
discontinued the study before week 8 were evaluated for 
tumour response during the last visit. All patients who 
received ≥1 dose of trebananib and had a baseline and 
at least one postdose assessment of tumour burden were 
included in this analysis set. Tumour burden was defined 
as the sum of the longest diameters (SLD) for up to 10 
target lesions.
Statistical analysis
Tolerability, PK, and tumor measurements and 
response results are expressed with descriptive statistics. 
For biomarker analyses, log–transformed analyte values 
were tested for changes from baseline to the treatment 
time points. Statistical significance (P<0.01) for change 
from baseline was based on the analysis of variance using 
an F–test.
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